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Background: Chronic kidney disease (CKD) is predominantly managed in primary care in the UK, but there is
evidence of under-identification leading to lack of inclusion on practice chronic disease registers, which are
necessary to ensure disease monitoring. Guidelines for CKD patients recommend urinary albumin to creatinine
ratio (uACR) testing to identify albuminuria to stratify risk and guide management. This study aimed to describe
the pattern and associations of timely CKD registration and uACR testing.
Methods: A retrospective cohort of individuals with incident CKD 3–5 (two estimated glomerular filtration rates
(eGFR) <60 ml/min/1.73 m2≥ three months apart) between 2007 and 2013 was identified from a linked database
containing primary and secondary care data. Descriptive statistics and Cox proportional hazards models were used
to identify associations with patient characteristics of timely CKD registration and uACR testing (within a year of
first low eGFR).
Results: 12,988 people with CKD 3–5 were identified from 88 practices and followed for median 3.3 years. During
this time period, 3235 (24.9%) were CKD-registered and 4638/12,988 (35.7%) had uACR testing (median time to CKD
registration 307 days and to uACR test 379 days). 1829 (14.1%) were CKD-registered and 2229 (17.2%) had uACR
testing within one year. Amongst people whose CKD was registered within a year, 676/1829 (37.0%) had uACR
testing within a year (vs. 1553/11,159 (13.9%) of those not registered (p < 0.001)). Timely uACR testing varied by
year, with a sharp rise in proportion in 2009 (when uACR policy changed). Timely CKD registration was independently
associated with lower eGFR, being female, earlier year of joining the cohort, having diabetes, hypertension, or
cardiovascular disease but not with age. Timely uACR testing was associated with timely CKD registration, younger
age, having diabetes, higher baseline eGFR and later year of joining the cohort.
Conclusions: Better systems are needed to support timely CKD identification, registration and uACR testing in primary
care in order to facilitate risk stratification and appropriate clinical management.
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There is strong evidence from international meta-
analyses of cohort studies that low estimated glomerular
filtration rate (eGFR) and albuminuria are independent
risk factors for poor clinical outcomes including all-cause
and cardiovascular mortality, progression of chronic kid-
ney disease (CKD) and acute kidney injury (AKI) [1-3].* Correspondence: s.fraser@soton.ac.uk
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unless otherwise stated.These associations exist in men and women, vary with
age, and occur in people with and without diabetes or
hypertension [4-8]. CKD and AKI are important causes of
hospitalisation and high healthcare costs. The total cost of
CKD to the English NHS in 2009/10 has been estimated
at £1.44 billion, over half of which was related to renal
replacement therapy (dialysis and transplant) [9-11].
Guidelines recommend urinary albumin to creatinine ratio
(uACR) testing to identify albuminuria in CKD (rather
than protein to creatinine ratio or dipstick testing), with
subsequent use of renin-angiotensin aldosterone systemThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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teinuria as a means of reducing risk of CKD progression
and cardiovascular disease (CVD) [12-14].
CKD identification has been the focus of several policy
initiatives in the UK. The National Service Framework
for Renal Services 2004/05 led to national reporting of
eGFR by clinical biochemistry laboratories from 2006
[15], the General Practice pay for performance Quality
and Outcomes Framework (QOF) included targets for
specific CKD management indicators (following inclu-
sion on a practice CKD register) from 2006/7 [16], the
National Institute for Health and Care Excellence
(NICE) introduced CKD guidelines in 2008 [12], and the
NHS Vascular Checks Programme (from 2009) includes
screening for CKD (stage 3–5) by eGFR measurement in
people aged 35–74 with newly-identified type 2 diabetes
or hypertension [17]. Despite these efforts, there is evi-
dence that CKD is under-registered in Primary Care
[18]. In 2013 NHS Kidney Care demonstrated wide vari-
ation in age-standardised prevalence of registered CKD
between GP practices [19]. In England in 2012/13 the
average registered CKD prevalence was 3.4% [20] com-
pared with 7.3% in the Quality Improvement in CKD
(QICKD) study (which used primary care biochemistry
data to define CKD) [21], and 5.2% in the Health Survey
for England [22]. In a recent large cohort study using
routine data in the UK, about 28% of people with bio-
chemically confirmed CKD were not labelled with a
CKD Read diagnostic code (and therefore not registered)
[23]. CKD diagnosis and registration require a logical
series of steps to be taken by clinicians based on eGFR
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Figure 1 Procedures leading to CKD registration. Key: Green boxes indpatient record by GPs lead to automatic registration, the
timeliness of registration reflects the speed with which
GPs recognize a new diagnosis of CKD. CKD under-
registration may arise from diagnostic challenges, such
as the need for repeat blood testing after three months,
but clinicians’ concerns about CKD over-diagnosis, par-
ticularly in the elderly, and anxiety about communicat-
ing the diagnosis may also adversely influence CKD
registration [24,25].
Since 2009, uACR testing has been included in Quality
and Outcomes Framework CKD targets (although the
diabetes domain has included microalbuminuria testing
since 2004) [16], but target achievement data does not
allow for assessment of the timeliness of CKD registra-
tion or uACR testing in relation to low eGFR results
[20]. The aims of this study were to describe the associa-
tions of firstly CKD registration and secondly uACR
testing within one year of first low eGFR in a population
of people with biochemically-defined CKD.
Methods
A retrospective cohort of people over 18 with incident
CKD between 01/01/2007 and 16/05/2013 was identified
from routine clinical biochemistry data using the Hamp-
shire Health Record analytical database (HHR). The
HHR is a shared clinical record containing anonymised
individual linked extracts of clinical records from ap-
proximately 150 GP practices in Hampshire and two
hospitals (University Hospital Southampton NHS Foun-
dation Trust and Portsmouth Hospitals NHS Trust),
including pathology results, with a total registered popu-
lation of >1.1 million people. Changes in practice clinicalCKD 3-5 already 
registered
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data to the HHR and practices without consistent path-
ology data throughout the study period were excluded.
Incident CKD stage 3 – 5 was defined as two values of
eGFR < 60 ml/min/1.73 m2 at least three months apart
(with no prior CKD diagnosis) according to guidelines
[12-14]. People with intervening eGFR values > 60 ml/
min/1.73 m2 were not considered as having CKD to ex-
clude people with transient falls in eGFR. Study entry
was defined as date of first eGFR < 60 ml/min/1.73 m2
because this indicated the earliest identifiable point of
the incident CKD occurrence and represents the earliest
point at which a clinician could have observed an abnor-
mality of renal function. The clinical biochemistry de-
partments confirmed that, during the study period,
eGFR was calculated using the simplified Modification
of Diet in Renal Disease equation and creatinine assays
conducted using standardised Jaffe’s assay method, with
calibration traceable to a standard reference material
(isotope dilution-mass spectrometry) [26-28].
Age was defined as age at study entry. Socioeconomic
status was assessed using quintiles of the England rank of
the Index of Multiple Deprivation (IMD, 1 =most de-
prived, 5 = least deprived) as single entry at data extraction
[29]. Ethnicity was poorly recorded in these data (esti-
mated <40%) and was not included in analyses. Relevant
clinical diagnoses were identified and classified using
standard Read code hierarchy lists [30]. CKD registration
status (registration / non-registration) was identified using
CKD stage 3–5 Read codes, and uACR testing status from
pathology records (see Additional file 1 for Read codes
used). Hypertension, diabetes and CVD were defined by
history of the diagnosis (presence of relevant Read code)
in GP records at study entry. Diabetes included all type 1
and type 2 codes and CVD included codes for cerebral in-
farct, cerebral thrombosis, ischaemic heart disease, hyper-
tensive heart disease, intracerebral haemorrhage, stroke,
transient ischemic attack, or peripheral vascular disease.
CVD was included because of the high degree of CVD co-
morbidity in this predominantly elderly population. It was
also perceived that the presence of any of these comorbid-
ities may influence CKD registration behaviour among
clinicians. Mortality was defined by death recorded in the
GP or hospital record.
Ethics
Use of the Hampshire Health Record for research is reg-
ulated by the Hampshire Health Record Advisory Group
(HHRAG) and the NHS South Commissioning Support
Unit Business Intelligence team. HHR data is pseudony-
mized and therefore it is not possible to identify patients.
These governance mechanisms mean that data from the
HHR can be examined with HHRAG approval but with-
out the need for formal ethical approval.Statistical analyses
Descriptive statistics were used to summarise the charac-
teristics of the study population by their CKD registration
status i.e. registered as having CKD for the Quality and
Outcomes Framework or tested for uACR between 01/01/
2007-16/05/2013 and the primary outcome of timely
registration and uACR testing (defined as occurrence
within a year of the date of first eGFR < 60 ml/min/
1.73 m2). Chi squared test was used to compare categor-
ical variables. Univariate, age-sex adjusted and multivari-
able Cox regression was used to identify the associations
of timely CKD registration and uACR testing. Cox propor-
tional hazards assumptions were checked. A time period
of one year from study entry was chosen because we con-
sidered this a reasonable time to allow for repeat eGFR
testing after three months (to confirm CKD) and a further
nine months to allow for CKD registration and a uACR
testing. Participants were censored at one year or at the
end of registration with the last registered practice (for
example if they moved away), death, or 16/05/2013 (data
extraction date) if these occurred sooner. (Analyses con-
ducted on those moving away within a year or on those
joining the cohort at the end of 2012 may therefore not
have allowed a full year of follow up).
To allow for the possibility that proteinuria had been
assessed using urinary protein to creatinine ratio (uPCR)
rather than uACR, we also identified those tested for
uPCR between 01/01/2007-16/05/2013 and conducted
sensitivity analyses of the Cox regression models with
‘uACR OR uPCR within a year’ as the outcome of interest.
Analyses were conducted using STATA version 12.1
and SAS version 9.3.
Results
Of the 499,997 people with complete data, 93,406 (18.7%)
had at least one eGFR < 60 ml/min/1.73 m2. Only a small
number of those (6044, 6.5%) had no further eGFR testing
(Figure 2). We identified 12,988 people who met the cri-
teria for incident CKD 3–5 (Figure 2) and followed them
up for a median of 3.3 years.
CKD registration within a year
Of the incident CKD study population, 3235/12,988
(24.9%) people were CKD-registered at some point be-
tween 2007 and 2013 (median time to registration
307 days (interquartile range (IQR) 100 to 629 days). Of
those who were ever CKD-registered, 1829/3235 (56.5%)
were registered within one year of their first low eGFR
(Table 1). This represented 14.1% of the total study popu-
lation with CKD (n = 12,988). A higher proportion of
people with poor baseline renal function (eGFR <30 ml/
min/1.73 m2 i.e. CKD 4–5) were CKD-registered within a
year (52/327; 15.9%) than those with better renal function
(eGFR ≥45 ml/min/1.73 m2 i.e. CKD 3a, 1542/11,450;
Total number of practices in the geographic area of the HHR = 233
Number of practices with any records in the HHR = 154
Number of practices with adequate pathology records in the HHR 
during the study period = 91
79 practices excluded that did not submit data 
to the HHR  
Pathology data
63 practices excluded with no pathology data 
(sending pathology requests to other hospitals)
Number of practices meeting both the practice data and pathology 
data criteria = 88
3 practices excluded without pathology and 
matching surgery data for 2008 
Practice exclusion
Total over 18 population of the 88 eligible GP practices = 500,019
Population with complete data = 499,997
Participant exclusion
No age/sex information = 22
24,118 with prevalent CKD at start of study 
period
Final cohort: individuals with two eGFR values < 60ml/min/1.73m2
at least 3 months apart 2007-2013 with no previous CKD diagnosis 
i.e. incident CKD = 12,988
Never had eGFR = 143,617 
Population who ever had an eGFR = 356,380
Population with at least one eGFR<60ml/min/1.73m2 = 93,406
No eGFR<60ml/min/1.73m2 = 262,974 
Population meeting study CKD criteria = 37,106
Single eGFR<60ml/min/1.73m2 only (no 
subsequent testing) = 6044
Population with at least two eGFR<60ml/min/1.73m2 = 87,362
Population with at least two eGFR<60ml/min/1.73m2 = 72,019
Two eGFRs<60ml/min/1.73m2 but >2 weeks 
and <3 months apart = 15,343
People with other patterns of eGFR testing 
not meeting CKD criteria = 34,913
Figure 2 Flow chart of study population identification in the Hampshire Health Record (HHR).
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with diabetes, hypertension or CVD were CKD-registered
within a year. CKD registration within a year did not
vary significantly by deprivation status (Table 1). On
univariate Cox regression analysis, women, people with
comorbidities (diabetes, hypertension or CVD) and
people with lower eGFR were more likely to be CKD-
registered within one year. People study-diagnosed as
CKD in later years of the cohort were less likely to have
timely CKD-registration. These associations remained
after adjustment for diabetes, hypertension, CVD, base-
line eGFR, deprivation and year of joining the cohort
(Table 2). Quality and Outcomes Framework ‘exception
reporting’ for CKD was identified in 354 people (2.7%).‘Exception reporting’ in the Quality and Outcomes
Framework allows clinicians to exclude patients from
recall (though they have CKD) in particular circum-
stances where this would be inappropriate, such as ter-
minal illness or extreme frailty.
uACR and uPCR testing within a year
In the study population, 4638/12,988 (35.7%) people had
a uACR test between 2007 and 2013, and 2229/12,988
(17.2%) people were tested within a year. Median time to
first uACR test was 379 days (IQR 150 to 715 days). By
comparison, 965/12,988 (7.4%) people had a uPCR test
between 2007 and 2013, and 429/12,988 (3.3%) people
were tested within a year. Median time to first uPCR test
Table 1 Characteristics of the study population (incident CKD) by CKD registration status
Variable Category CKD registered within
1 year (n = 1829)
Not CKD registered
within 1 year (n = 11,159)
Total (n = 12,988)
n Column % n Column % n Column % p value
Sex Male 836 45.7 4627 41.5 5463 42.1 0.001
Female 993 54.3 6532 58.5 7525 57.9
Age at study entry <50 34 1.85 394 3.5 428 3.3 0.001
50-69 470 25.7 2921 26.1 3391 26.1
70-79 699 38.2 4274 38.3 4973 38.3
80+ 626 34.2 3570 32.0 4196 32.3
IMD quintile 1 (most deprived) 156 8.5 1034 9.3 1190 9.2 0.33
2 266 14.5 1536 13.8 1802 13.9
3 412 22.5 2324 20.8 2736 21.1
4 424 23.1 2674 24.0 3098 23.9
5 (least deprived) 570 31.2 3582 32.1 4152 32.0
CVD at study entry Yes 547 29.9 2927 26.2 3474 26.7 0.001
No 1282 70.1 8232 73.8 9514 73.3
Hypertension at study entry Yes 1146 62.6 6049 54.2 7195 55.4 <0.001
No 683 37.3 5110 45.8 5793 44.6
Diabetes at study entry Yes 344 18.8 1707 15.3 2051 15.8 <0.001
No 1485 81.2 9452 84.7 10,937 84.2
eGFR at study entry (ml/min/1.73 m2) ≥45 1542 84.3 9908 88.8 11,450 88.2 <0.001
30-44 235 12.8 976 8.7 1211 9.3
15-29 40 2.2 182 1.6 222 1.7
<15 12 0.7 93 0.8 105 0.8
uACR test within 1 year Yes 676 37.0 1553 13.9 2229 17.2 <0.001
No 1153 63.0 9606 86.1 10,759 82.8
Abbreviations in Table 2: CKD chronic kidney disease, IMD Index of multiple deprivation, BP blood pressure, eGFR estimated Glomerular Filtration Rate, CVD
cardiovascular disease.
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uPCR had been tested in 529/12,988 (4.1%) people and
101 (0.8%) had both tested within a year. A total of
5074/12,988 (39.1%) had some form of laboratory pro-
teinuria assessment (i.e. uACR or uPCR) of whom 2557/
12,988 (19.7%) had it within a year.
Although the overall proportion of people tested
within a year remained below 25%, there was an increase
over time with a notable step change in 2009 (Figure 3).
Among the 1829 people whose CKD was registered
within a year, 676 (37.0%) also had uACR testing within
a year (vs.1553/11,159 (13.9%) of those not registered
within a year). On univariate analyses, females, younger
people, people from less deprived areas, people with
higher baseline eGFR, people with diabetes, people with
CVD, people joining the cohort later and people whose
CKD was registered within one year were more likely to
have timely uACR testing (Table 3). These associations
were maintained for younger people, diabetes, baseline
eGFR, later entrants to the cohort, and people whoseCKD was registered within one year in the fully adjusted
model. The associations were similar in the sensitivity
analyses (with uACR or uPCR within a year as the
outcome of interest) except that female gender and
hypertension were independently associated with timely
proteinuria testing.
Discussion
This study has shown in a large population of people
with incident CKD defined from routine biochemistry
data, timely CKD registration and uACR testing were
poor. Only a quarter were registered as having CKD
(CKD registration) after median follow up of about
3 years and 14.1% were registered within a year of first
low eGFR (median time to CKD registration 0.8 years).
Women, people with hypertension, diabetes or CVD and
people with lower eGFR were more likely to have been
CKD registered within a year. Age was not associated
with CKD registration, but people with incident CKD
from 2008 onwards were less likely to be registered
Table 2 Cox regression analysis of CKD registration within 12 months (1829 events of total n = 12,988)
Variable Category Univariate Multivariable*
HR (95% CI) p HR (95% CI) p
Sex (female vs. male) 1.17 (1.10-1.27) 0.001 1.19 (1.08-1.30) 0.001
Age (continuous) 1.00 (1.00-1.01) 0.058 1.00 (1.00-1.01) 0.546
IMD quintile (vs. least deprived) 1 (most deprived) 0.95 (0.79-1.13) 0.324 0.92 (0.88-1.13) 0.381
2 1.08 (0.94-1.25) 1.07 (0.96-1.23)
3 1.10 (0.97-1.25) 1.09 (0.92-1.23)
4 1.00 (0.88-1.13) 0.99 (0.77-1.11)
Cardiovascular disease at baseline (vs no CVD) 1.19 (1.10-1.29) 0.001 1.11 (1.00-1.23) 0.049
Diabetes at baseline (vs. no diabetes) 1.25 (1.10-1.32) 0.001 1.21 (1.08-1.37) 0.002
Hypertension at baseline (vs. no hypertension) 1.39 (1.14-1.32) <0.001 1.36 (1.23-1.49) <0.001
Baseline eGFR (continuous, ml/min/1.73 m2) 0.99 (0.99-1.00) <0.001 0.99 (0.98-0.99) <0.001
Year of joining cohort (vs. 2007) 2008 0.67 (0.53-0.84) <0.001 0.71 (0.56-0.89) <0.001
2009 0.54 (0.43-0.69) 0.58 (0.46-0.74)
2010 0.42 (0.33-0.54) 0.44 (0.34-0.57)
2011 0.46 (0.36-0.60) 0.49 (0.38-0.63)
2012 0.41 (0.33-0.57) 0.46 (0.34-0.60)
*adjusted for age, sex, index of multiple deprivation, cardiovascular disease, hypertension, diabetes, baseline eGFR, year of joining cohort.
Abbreviations in Table 3: CKD chronic kidney disease, IMD Index of multiple deprivation, BP blood pressure, eGFR estimated Glomerular Filtration Rate, CVD
cardiovascular disease.
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further investigation, particularly in the context of an in-
crease in uACR testing following the change in incen-
tives in 2009 (to include uACR, though there was no
change in the CKD registration incentive). About a third
of people with study-identified CKD had uACR tested at
some point during the study period and 8% were tested
within a year of first low eGFR (median time to uACR
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Figure 3 Proportion of people with uACR and uPCR testing within a yCKD registration and joining the cohort later were posi-
tively associated with uACR testing. Associations with
timely uACR or uPCR testing also included female sex
and hypertension, although numbers tested for uPCR
were low compared with uACR.
Strengths and limitations
Strengths included the large study size, its population-
based approach, and use of biochemically-defined CKD09 2010 2011 2012
uACR
uPCR
ear by year of joining the cohort.
Table 3 Cox regression analysis of uACR testing within 12 months (2229 events of total n = 12,988)
Variable Category Univariate Multivariable*
HR (95% CI) p HR (95% CI) p
Sex (female vs. male) 1.42 (1.31-1.54) <0.001 1.09 (1.00-1.19) 0.438
Age (continuous) 0.99 (0.98-0.99) <0.001 0.99 (0.99-1.00) 0.028
IMD quintile (vs. least deprived) 1 (most deprived) 1.20 (1.03-1.40) <0.001 0.88 (0.75-1.02) 0.135
2 1.29 (1.13-1.46) 1.05 (0.92-1.19)
3 1.13 (1.01-1.27) 0.98 (0.87-1.10)
4 0.97 (0,86-1.09) 0.91 (0.81-1.02)
Cardiovascular disease at baseline (vs. no CVD) 1.27 (1.16-1.39) <0.001 0.948 (0.86-1.04) 0.260
Diabetes at baseline(vs. n diabetes) 10.24 (9.41-11.14) <0.001 9.32 (8.54-10.18) <0.001
Hypertension at baseline (vs. no hypertension) 1.46 (1.34-1.59) <0.001 1.06 (0.97-1.16) 0.215
Baseline eGFR (continuous) 1.01 (1.01-1.02) <0.001 1.01 (1.00-1.01) 0.014
Year of joining cohort (vs. 2007) 2008 1.08 (0.75-1.56) <0.001 1.24 (0.86-1.79) <0.001
2009 2.09 (1.46-2.99) 2.56 (1.78-3.68)
2010 2.30 (1.60-3.30) 2.65 (1.84-3.82)
2011 2.34 (1.63-3.38) 2.73 (1.89-3.94)
2012 2.65 (1.83-3.83) 2.54 (1.75-3.69)
CKD registration within a year (vs. not) 2.94 (2.69, 3.22) <0.001 2.79 (2.55-3.06) <0.001
*adjusted for age, sex, index of multiple deprivation, cardiovascular disease, hypertension, diabetes, baseline eGFR, year of joining cohort, CKD registration
within 1 year.
Abbreviations in Table 3: CKD chronic kidney disease, IMD Index of multiple deprivation, BP blood pressure, eGFR estimated Glomerular Filtration Rate,
CVD cardiovascular disease.
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limitations. Use of routine data may lead to underesti-
mation of true CKD incidence (case identification relied
on routine blood testing, though testing is higher in
older age groups who have the highest prevalence) [31].
Missing data precluded assessment of the influence of
ethnicity on CKD registration and uACR testing, al-
though the study area has a lower than national ethnic
minority population prevalence. This limits the general-
isability of this study to areas with greater ethnic diver-
sity. We could not identify changes in Index of Multiple
Deprivation (linked to area of residence) over time, po-
tentially misclassifying deprivation status in some who
moved during the study. Other proteinuria testing
methods (such as urine dipstick) were not assessed; we
may therefore have underestimated efforts to ascertain
proteinuria status. However, our research question re-
lated to uACR / uPCR testing as this is recommended in
CKD guidelines [12,16]. Restricting inclusion of general
practices to those with available data across the whole
study period improved validity of results, but reduces
generalisability. An important limitation is that we were
unable to identify registered practice or individual GP at
date of first low eGFR, so could not include these as var-
iables in our models. We were therefore unable to adjust
for differing GP or practice characteristics that may have
influenced CKD registration or to account for clustering
within practice. Finally, it was beyond the remit of thisstudy to compare other quality of care measures, such as
BP control, CVD risk assessment, statin and RAASi use
in those registered/not registered. These are important
considerations for future research.
Comparison with existing literature
To our knowledge, this is the first study to explore factors
associated with timely CKD registration and uACR testing.
The New Opportunities for Early Renal Intervention by
Computerised Assessment (NEOERICA) study identified
a higher prevalence of biochemically-defined than diag-
nosed renal disease (8.5% vs. 1.6% respectively) [32] but
NEOERICA was carried out prior to the introduction of
CKD in the Quality and Outcomes Framework and is
therefore not directly comparable. Following its inclusion
in the Quality and Outcomes Framework, CKD registra-
tion increased in primary care (from 2.4 to 4.3% between
2007 and 2011) [33], but our study demonstrates that
many patients with probable CKD are not entered onto a
CKD register or uACR tested so remain more likely to
miss out on treatments that are effective in preserving
renal function. McIntyre et al. [18] have shown that many
patients identified with CKD could benefit from more in-
tensive treatment, for instance closer BP control, but
qualitative research has highlighted tensions about how
best to implement structured care for CKD in primary
care [25]. In 2013, NHS Kidney Care made several recom-
mendations for GP practices to help CKD identification
Fraser et al. BMC Family Practice  (2015) 16:18 Page 8 of 10including conducting audit to search for ‘missing’ CKD
patients and ensuring awareness of CKD among clinical
staff. [19] Our study suggests that having hypertension
may influence CKD registration. This is reassuring as good
BP control is probably the most important primary care
intervention for people with CKD [34,35]. The lack of as-
sociation between age and CKD registration suggests that
older age does not adversely influence clinical decision to
register. Lower baseline eGFR was appropriately associ-
ated with greater likelihood of CKD registration.
Achievement of individual QOF clinical indicators, in-
cluding uACR testing, relies on accurately identifying and
coding the underlying condition (to establish the prevalent
population). Unsurprisingly, our study suggested that
CKD registration influenced uACR testing. Timely uACR
testing was better from 2009, consistent with the introduc-
tion of uACR as a CKD QOF indicator that year. Better
testing among people with diabetes (though still subopti-
mal) may reflect greater clinician concern about diabetic
nephropathy than CKD per se and/or diabetes albumin-
uria testing guidelines predating CKD ones [36]. Variation
in QOF achievement can also arise from differences in ex-
ception reporting behaviour (the removal of patients
judged by GPs to be inappropriate from calculations of
quality achievement) but this was thought to be unlikely
to explain our findings as the proportion with exception
reporting was low. It is reassuring that we found no evi-
dence of a social gradient in uACR testing as albuminuria
prevalence was higher in lower socioeconomic groups in
the Health Survey for England [22], and the QICKD study
identified an association between lack of renal function
monitoring (including proteinuria assessment) and ad-
verse outcomes [37].
Implications for research and practice
Delay or failure in CKD registration and uACR testing
has implications for quality of care in people with CKD
by reducing the possibility of early intervention to re-
duce future risk. In the context of growing pressures on
primary care teams and the complexity of diagnosing
CKD, our study supports the use of electronic record
searching using tools such as IMPAKT™ to identify CKD
rather than relying on manual coding [38]. This supports
a similar recommendation made by Jain and colleagues
in their recent UK-based cohort study, who identified
that those not coded as having CKD received sub-
optimal care [23]. Given the importance of albuminuria
in risk stratification and as a prognostic indicator of
CVD and AKI, the association between uACR testing
and CKD registration in this study is a strong argument
for improving timely CKD registration [1-8,39]. CKD
identification with registration is more likely to lead
to interventions such as assessment of cardiovascular
risk [40,41], control of blood pressure [42], use of RAASi(based on albuminuria status) [43] and lipid lowering
therapies in those with elevated CVD risk [44]. CKD
registration and uACR measurement are therefore im-
portant quality issues that appropriately form part of the
National CKD audit in England and Wales. Our study
suggests that equity by gender should be an important
consideration. In light of the high cost of renal replace-
ment therapy, clarifying the extent to which the identifi-
cation of CKD and albuminuria and their appropriate
management has the potential to reduce CKD progres-
sion to end stage renal disease represent areas for future
investigation. This study also highlights the need to inves-
tigate outcomes among people with different patterns of
eGFR testing, such as those who only had one low eGFR
with no subsequent investigation and those with transient
eGFR changes, some of whom may have community-
acquired acute kidney injury [45].
Conclusions
This study has identified the need to strengthen systems
to identify/register CKD and test for albuminuria in a
timely fashion in primary care. Risk stratification is
greatly improved by recording both eGFR and uACR
status in people with CKD. Better systems of CKD iden-
tification and albuminuria assessment would enhance
risk-reducing efforts.
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